Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.
CONCLUSION: Elbasvir-grazoprevir achieves a high cure rate in the treatment of patients with chronic HCV with a once-daily oral regimen and without serious adverse effects; however, it requires close monitoring of liver function values. It is an effective option for patients with HCV genotype 1a, 1b, or 4 with or without compensated cirrhosis and is a particularly attractive option in patients with chronic kidney disease receiving hemodialysis and in patients with HIV coinfection.
PMID: 28947524 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Karaoui LR, Mansour H, Chahine EB Tags: Am J Health Syst Pharm Source Type: research
More News: Chemistry | Chronic Kidney Disease | Cirrhosis | Clinical Trials | Dialysis | Drugs & Pharmacology | Headache | Hemodialysis | Hepatitis | Hepatitis C | Liver | Migraine | Urology & Nephrology | Virology